Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 465

1.

Effect of renal function on whole blood and fibrin clot formation in atrial fibrillation patients on warfarin.

Lau YC, Xiong Q, Lip GY, Blann AD.

Ann Med. 2016 Jun;48(4):275-81. doi: 10.3109/07853890.2016.1166516. Epub 2016 Apr 4.

PMID:
27043881
2.

Periprocedural Management of Patients on a Vitamin K Antagonist or a Direct Oral Anticoagulant Requiring an Elective Procedure or Surgery.

Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD.

J Thromb Haemost. 2016 Mar 14. doi: 10.1111/jth.13305. [Epub ahead of print] Review.

PMID:
26988871
3.

Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation: A Registry Study.

Vestergaard AS, Skjøth F, Lip GY, Larsen TB.

Stroke. 2016 Apr;47(4):979-85. doi: 10.1161/STROKEAHA.115.012338. Epub 2016 Feb 16.

PMID:
26883499
4.

Periprocedural warfarin reversal with prothrombin complex concentrate.

Sridharan M, Wysokinski WE, Pruthi R, Oyen L, Freeman WD, Rabinstein AA, McBane RD.

Thromb Res. 2016 Mar;139:160-5. doi: 10.1016/j.thromres.2015.11.024. Epub 2015 Nov 18.

PMID:
26657301
5.
6.

Relationship of Age With Stroke and Death in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: AMADEUS Trial.

Senoo K, Lip GY.

Stroke. 2015 Nov;46(11):3202-7. doi: 10.1161/STROKEAHA.115.010614. Epub 2015 Oct 13.

PMID:
26463692
7.

Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage.

Witt DM, Clark NP, Martinez K, Schroeder A, Garcia D, Crowther MA, Ageno W, Dentali F, Ye X, Hylek E, Delate T.

Thromb Res. 2015 Nov;136(5):1040-4. doi: 10.1016/j.thromres.2015.10.002. Epub 2015 Oct 9.

PMID:
26454758
8.

TO BLEED OR NOT TO BLEED: THAT IS THE QUESTION. THE SIDE EFFECTS OF APIXABAN.

Ciccone MM, Zito A, Devito F, Maiello M, Palmiero P.

Curr Drug Targets. 2015 Oct 1. [Epub ahead of print]

PMID:
26424386
9.

Risk of Venous Thromboembolism After Receiving Prothrombin Complex Concentrate for Warfarin-associated Intracranial Hemorrhage.

Felton D, Foley EM, Traub SJ, Vodonos A, Ganetsky M.

J Emerg Med. 2016 Jan;50(1):1-6. doi: 10.1016/j.jemermed.2015.07.001. Epub 2015 Sep 26.

PMID:
26409668
10.

Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study.

Blann AD, Banerjee A, Lane DA, Torp-Pedersen C, Lip GY.

Int J Cardiol. 2015 Dec 15;201:693-8. doi: 10.1016/j.ijcard.2015.08.074. Epub 2015 Aug 10.

PMID:
26379097
11.

Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.

Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators.

JAMA. 2015 Aug 18;314(7):677-86. doi: 10.1001/jama.2015.9243.

PMID:
26284719
12.

Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist.

Carles M, Brosa M, Souto JC, Garcia-Alamino JM, Guyatt G, Alonso-Coello P.

BMC Health Serv Res. 2015 Jul 28;15:289. doi: 10.1186/s12913-015-0934-9.

13.

Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke.

Yaghi S, Kamel H, Elkind MS.

Neurology. 2015 Sep 22;85(12):1078-84. doi: 10.1212/WNL.0000000000001817. Epub 2015 Jul 17. Review.

PMID:
26187229
14.

Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.

Couturaud F, Sanchez O, Pernod G, Mismetti P, Jego P, Duhamel E, Provost K, dit Sollier CB, Presles E, Castellant P, Parent F, Salaun PY, Bressollette L, Nonent M, Lorillon P, Girard P, Lacut K, Guégan M, Bosson JL, Laporte S, Leroyer C, Décousus H, Meyer G, Mottier D; PADIS-PE Investigators.

JAMA. 2015 Jul 7;314(1):31-40. doi: 10.1001/jama.2015.7046.

PMID:
26151264
15.

The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.

Gonda DD, Fridley J, Ryan SL, Briceño V, Lam SK, Luerssen TG, Jea A.

J Neurosurg Pediatr. 2015 Sep;16(3):329-34. doi: 10.3171/2015.1.PEDS14489. Epub 2015 Jun 12.

PMID:
26067336
16.

Bleeding, Recurrent Venous Thromboembolism, and Mortality Risks During Warfarin Interruption for Invasive Procedures.

Clark NP, Witt DM, Davies LE, Saito EM, McCool KH, Douketis JD, Metz KR, Delate T.

JAMA Intern Med. 2015 Jul;175(7):1163-8. doi: 10.1001/jamainternmed.2015.1843.

17.

Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital.

Tellor KB, Patel S, Armbruster AL, Daly MW.

J Clin Pharm Ther. 2015 Aug;40(4):447-51. doi: 10.1111/jcpt.12288. Epub 2015 May 26.

PMID:
26010016
18.

Risks and benefits of low molecular-weight heparin and target-specific oral anticoagulant use for thromboprophylaxis in medically ill patients.

Hale G, Brenner M.

Am J Cardiovasc Drugs. 2015 Oct;15(5):311-22. doi: 10.1007/s40256-015-0122-7. Review.

PMID:
25957095
19.

Declining Long-term Risk of Adverse Events after First-time Community-presenting Venous Thromboembolism: The Population-based Worcester VTE Study (1999 to 2009).

Huang W, Goldberg RJ, Cohen AT, Anderson FA, Kiefe CI, Gore JM, Spencer FA.

Thromb Res. 2015 Jun;135(6):1100-6. doi: 10.1016/j.thromres.2015.04.007. Epub 2015 Apr 11.

PMID:
25921936
20.

Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study).

Nakamura M, Nishikawa M, Komuro I, Kitajima I, Uetsuka Y, Yamagami T, Minamiguchi H, Yoshimatsu R, Tanabe K, Matsuoka N, Kanmuri K, Ogawa H.

Circ J. 2015;79(6):1230-6. doi: 10.1253/circj.CJ-15-0195. Epub 2015 Apr 24. Erratum in: Circ J. 2015;79(11):2520.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk